Abstract:Increasing evidence suggests that the calcium-binding and proinflammatory protein S100A9 is an important player in neuroinflammation-mediated Alzheimer's disease (AD). The amyloid co-aggregation of S100A9 with amyloid-β (Aβ) is an important hallmark of this pathology. Apolipoprotein E (ApoE) is also known to be one of the important genetic risk factors of AD. ApoE primarily exists in three isoforms, ApoE2 (Cys112/Cys158), ApoE3 (Cys112/Arg158), and ApoE4 (Arg112/Arg158). Even though the difference lies in just two amino acid residues, ApoE isoforms produce differential effects on the neuroinflammation and activation of the microglial state in AD. Here, we aim to understand the effect of the ApoE isoforms on the amyloid aggregation of S100A9. We found that both ApoE3 and ApoE4 suppress the aggregation of S100A9 in a concentration-dependent manner, even at sub-stoichiometric ratios compared to S100A9. These interactions lead to a reduction in the quantity and length of S100A9 fibrils. The inhibitory effect is more pronounced if ApoE isoforms are added in the lipid-free state versus lipidated ApoE. We found that, upon prolonged incubation, S100A9 and ApoE form low molecular weight complexes with stochiometric ratios of 1:1 and 2:1, which remain stable under SDS-gel conditions. These complexes self-assemble also under the native conditions; however, their interactions are transient, as revealed by glutaraldehyde cross-linking experiments and molecular dynamics (MD) simulation. MD simulation demonstrated that the lipid-binding C-terminal domain of ApoE and the second EF-hand calcium-binding motif of S100A9 are involved in these interactions. We found that amyloids of S100A9 are cytotoxic to neuroblastoma cells, and the presence of either ApoE isoforms does not change the level of their cytotoxicity. A significant inhibitory effect produced by both ApoE isoforms on S100A9 amyloid aggregation can modulate the amyloid-neuroinflammatory cascade in AD.

Calcium-mediated amyloid co-aggregation of S100A1 and S100A8 proteins

Formation of Calprotectin Inhibits Amyloid Aggregation of S100A8 and S100A9 Proteins

The Stabilization of S100A9 Structure by Calcium Inhibits the Formation of Amyloid Fibrils

Morphological and Biophysical Study of S100A9 Protein Fibrils by Atomic Force Microscopy Imaging and Nanomechanical Analysis

S100a9 Induces Aggregation-Prone Conformation in Abeta Peptides: A Combined Experimental and Simulation Study

S100A9 Inhibits and Redirects Prion Protein 89-230 Fragment Amyloid Aggregation

S100B chaperone multimers suppress the formation of oligomers during Aβ42 aggregation

ApoE Isoforms Inhibit Amyloid Aggregation of Proinflammatory Protein S100A9

Dynamic interactions and Ca2+-binding modulate the holdase-type chaperone activity of S100B preventing tau aggregation and seeding

Divalent cations influence the dimerization mode of murine S100A9 protein by modulating its disulfide bond pattern

Calcium mediated static and dynamic allostery in S100A12: Implications for target recognition by S100 proteins

MRP14 (S100A9) Protein Interacts with Alzheimer Beta-Amyloid Peptide and Induces Its Fibrillization

Heterotypic droplet formation by pro-inflammatory S100A9 and neurodegenerative disease-related alpha-synuclein

Calcium-Dependent Translocation of S100B Is Facilitated by Neurocalcin Delta

Heterodimeric Interaction and Interfaces of S100A1 and S100P.

Unraveling the Mechanisms of S100A8/A9 in Myocardial Injury and Dysfunction

Secondary Modification of S100B Influences Anti Amyloid-β Aggregation Activity and Alzheimer's Disease Pathology

Understanding Calcium-Dependent Conformational Changes in S100A1 Protein: A Combination of Molecular Dynamics and Gene Expression Study in Skeletal Muscle

S100A6 and Its Brain Ligands in Neurodegenerative Disorders

Structural Insights into the Co-Aggregation of Aβ and Tau Amyloid Core Peptides: Revealing Potential Pathological Heterooligomers by Simulations.

Roles of S100A8, S100A9 and S100A12 in infection, inflammation and immunity